Abstract
Several converging lines of evidence from molecular, animal, and clinical studies have demonstrated that the gamma-aminobutyric type A (GABAA) receptor complex plays a central role in the modulation of anxiety. While currently available therapeutic agents that act on this receptor (e.g., benzodiazepines) are effective anxiolytics, they are limited by side effects, tolerance, and abuse potential. Promising strategies to address these limitations include the development of subunit-selective agonists and partial agonists, which specifically ameliorate anxiety without causing sedation or motor impairment. In vivo neuroimaging studies have identified several limbic and paralimbic brain regions involved in the generation or modulation of anxiety and fear responses, suggesting that the neuroinhibitory processes of GABAA receptors may be localized in certain brain areas which may serve as specific sites for drug action. Indeed, neurochemical brain imaging studies have reported decreased ligand binding to GABAA benzodiazepine receptors in prefrontal and medial temporal cortex in a variety of anxiety disorders. This paper reviews recent findings from molecular neuropsychopharmacology and in vivo neuroimaging of GABAA benzodiazepine receptors which offer novel perspectives on the genesis of normal anxiety and on pathophysiology of anxiety disorders. Collectively, these findings suggest several potentially successful avenues for future development of GABAA receptor-mediated anxiolytic treatments, and prompt further exploration of this neurochemical system in pathogenesis of anxiety disorders.
Keywords: gabaa receptor, anxiety, clinical psychopharmacology, brain imaging studies, benzodiazepines
Current Neuropharmacology
Title: Role of the GABAA Receptor in Anxiety: Evidence from animal models, molecular and clinical psychopharmacology, and brain imaging studies
Volume: 1 Issue: 3
Author(s): Israel Liberzon, K. Luan Phan, Samir Khan and James L. Abelson
Affiliation:
Keywords: gabaa receptor, anxiety, clinical psychopharmacology, brain imaging studies, benzodiazepines
Abstract: Several converging lines of evidence from molecular, animal, and clinical studies have demonstrated that the gamma-aminobutyric type A (GABAA) receptor complex plays a central role in the modulation of anxiety. While currently available therapeutic agents that act on this receptor (e.g., benzodiazepines) are effective anxiolytics, they are limited by side effects, tolerance, and abuse potential. Promising strategies to address these limitations include the development of subunit-selective agonists and partial agonists, which specifically ameliorate anxiety without causing sedation or motor impairment. In vivo neuroimaging studies have identified several limbic and paralimbic brain regions involved in the generation or modulation of anxiety and fear responses, suggesting that the neuroinhibitory processes of GABAA receptors may be localized in certain brain areas which may serve as specific sites for drug action. Indeed, neurochemical brain imaging studies have reported decreased ligand binding to GABAA benzodiazepine receptors in prefrontal and medial temporal cortex in a variety of anxiety disorders. This paper reviews recent findings from molecular neuropsychopharmacology and in vivo neuroimaging of GABAA benzodiazepine receptors which offer novel perspectives on the genesis of normal anxiety and on pathophysiology of anxiety disorders. Collectively, these findings suggest several potentially successful avenues for future development of GABAA receptor-mediated anxiolytic treatments, and prompt further exploration of this neurochemical system in pathogenesis of anxiety disorders.
Export Options
About this article
Cite this article as:
Liberzon Israel, Phan Luan K., Khan Samir and Abelson L. James, Role of the GABAA Receptor in Anxiety: Evidence from animal models, molecular and clinical psychopharmacology, and brain imaging studies, Current Neuropharmacology 2003; 1 (3) . https://dx.doi.org/10.2174/1570159033477071
DOI https://dx.doi.org/10.2174/1570159033477071 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Enhancing Neuropharmacology with Home Cage Monitoring, Advanced Delivery and Stimulation Technologies, and Artificial Intelligence
Home cage monitoring (HCM) technologies have revolutionized neuropharmacological research by enabling continuous, non-invasive observation of rodents in their natural environments. Complementary advancements such as 24/7 continuous drug delivery systems (e.g., implantable pumps) and wireless neurostimulation methods—including optogenetics—offer precise methods for modulating neural activity and administering pharmacological agents without disrupting the ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Ligand based Drug Design of New Heterocyclic Imines of GABA Analogues: A Molecular Docking Approach for the Discovery of New GABA-AT Inhibitors
Central Nervous System Agents in Medicinal Chemistry Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets Distinctive Clinico-electrographic and Radiological Profile of Childhood and Adolescent Seizures
Current Pediatric Reviews Role of Nitric Oxide and Calpain Activation in Neuronal Death and Survival
Current Drug Targets - CNS & Neurological Disorders Personalizing Medicine in Nigeria by Tailoring the Research Process: Points to Consider for Genomic Research
Current Pharmacogenomics and Personalized Medicine Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
Current Psychiatry Research and Reviews Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design The Role of Epigenetic Alterations Involved in Sepsis: An Overview
Current Pharmaceutical Design The Screening Program for Autism Spectrum Disorders in the West of Iran
Current Psychiatry Research and Reviews The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment
CNS & Neurological Disorders - Drug Targets Interleukin-4-Induced Oxidative Stress Via Microglial NADPH Oxidase Contributes to the Death of Hippocampal Neurons In Vivo
Current Aging Science A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery <i>In-situ</i> Gels for Brain Delivery: Breaching the Barriers
Current Pharmaceutical Design Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Design and Evaluation of Semicarbazones and Thiosemicarbazones as Novel Anticonvulsants
Central Nervous System Agents in Medicinal Chemistry Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§
CNS & Neurological Disorders - Drug Targets Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets